Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04723875 | Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline | active not recruiting | Phase 3 | 306 | Huazhong University of Science and TechnologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT01985087 | A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 | active not recruiting | Phase 1 / Phase 2 | 18 | University of LouisvilleOTHER | 1 | Oct 31, 2024 |
| clinicaltrials |
| NCT05118776 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | active not recruiting | Phase 3 | 136 | Ascletis Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05566041 | A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer(REPLATINUM) | active not recruiting | Phase 3 | 292 | EpicentRx, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05674422 | GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.(REVEAL) | active not recruiting | — | 120 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06667050 | CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer | active not recruiting | Phase 2 | 58 | West China HospitalOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT01843140 | Assessing Reproductive Outcomes in Young Female Cancer Survivors Through a National Fertility Preservation Registry | active not recruiting | — | 55 | University of California, San DiegoOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT02611570 | LDCT Screening in Non-smokers in Taiwan | active not recruiting | — | 12,000 | Academia Sinica, TaiwanOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04167631 | Can VI-RADS/ADC Accurately Stage Bladder Cancer?? | active not recruiting | N/A | 150 | Mansoura UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05426486 | A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | active not recruiting | Phase 2 / Phase 3 | 136 | Caigang LiuOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06664983 | TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT03603795 | Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy(EPAG2015) | active not recruiting | Phase 2 | 110 | French Innovative Leukemia OrganisationOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03609060 | Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)(DEXAML-02) | active not recruiting | Phase 2 | 120 | French Innovative Leukemia OrganisationOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06662643 | A Clinical Trial Comparing Staged Turnbull-Cutait Pull-through Anastomosis With Direct Anastomosis Plus Prophylactic Ileostomy in the Treatment of Low Rectal Cancer After Internal Sphincter Resection(STAR-TAR) | active not recruiting | N/A | 110 | Zhongnan HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06664190 | Pre-operative Surgical Difficulty Stratification Using Predicted Tumor Perfusion and Consistency | active not recruiting | — | 200 | Huashan HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT04161092 | The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases(SOULMATE) | active not recruiting | N/A | 45 | Vastra Gotaland RegionOTHER_GOV | 1 | Oct 28, 2024 | clinicaltrials |
| NCT04511871 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | active not recruiting | Phase 1 | 12 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT06635434 | An English/Spanish Mobile Augmented Reality Pain Assessment App for Hispanic/Latino Pediatric Cancer Patients | active not recruiting | Early Phase 1 | 16 | ALTality, Inc.INDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05548634 | A Study of TAVO412 in Patients with Cancer(TAVO412) | active not recruiting | Phase 1 | 50 | Tavotek BiotherapeuticsINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06497270 | A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial(DISC-OVARY) | active not recruiting | N/A | 3 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06654583 | Effectiveness of Developed Interactive Play Mat In Pediatric Physical Therapy | active not recruiting | N/A | 54 | Superior UniversityOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04475731 | Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse | active not recruiting | Phase 2 | 67 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05159440 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT03635021 | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer(CR-SEQUENCE) | active not recruiting | Phase 3 | 419 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05571618 | The Rechallenge of ADCs in MBC Patients | active not recruiting | — | 100 | Fudan UniversityOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06649591 | Expert Consensus and Artificial Intelligence in Medical Decision Making in Patients with Malignant Brain Tumors(EC-AIM Brain) | active not recruiting | — | 225 | Tufts Medical CenterOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT04624958 | Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL | active not recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05400070 | Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC | active not recruiting | Phase 2 | 45 | Tang-Du HospitalOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05659914 | Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations | active not recruiting | Phase 2 | 40 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT00102648 | Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05202782 | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | active not recruiting | Phase 2 | 24 | Northwestern UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06641700 | Predictive Value of Air Pollution and Metabolomics for Gastric Cancer. | active not recruiting | — | 200 | Dong PengOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06643429 | Impact of Environmental Factors and Metabolomics on Colorectal Cancer. | active not recruiting | — | 700 | Dong PengOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04584008 | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics(VISIONARY) | active not recruiting | N/A | 600 | Peking UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04806399 | Improving Utilization of Lung Cancer Screening in Underserved PA Populations | active not recruiting | N/A | 2,500 | American College of RadiologyOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05406401 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)(waveLINE-007) | active not recruiting | Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT06640153 | MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma | active not recruiting | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05709730 | Follow-up of Cell Changes in the Cervix | active not recruiting | — | 885 | Karolinska University HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03268876 | The INFLUENCE of Cytoreduction on PRO in EOC(INFLUENCE) | active not recruiting | — | 70 | Haukeland University HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT02647385 | Pain Control in Breast Surgery: Analgesia, Opioid Consumption and Inflammatory Response Evaluation | active not recruiting | N/A | 50 | Hospital Sirio-LibanesOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04652076 | GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab(GYNET) | active not recruiting | Phase 1 / Phase 2 | 240 | NETRIS PharmaINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06632106 | HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC | active not recruiting | — | 97 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT05177731 | Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML | active not recruiting | Phase 3 | 188 | Chen SuningOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03546426 | Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies(MESOVAX) | active not recruiting | Phase 1 | 18 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03230734 | Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer(RAPSON) | active not recruiting | Phase 2 | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04117945 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 22 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06026631 | Lipidomic Characterization in Non-metastatic Breast Cancer Women Undergoing Surgery: a Pilot Study.(BreCaLip) | active not recruiting | N/A | 65 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614660 | Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer | active not recruiting | — | 800 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Nov 1, 2024source: clinicaltrials